- Home
- IPSC vs MAIA Comparison
IPSC vs MAIA Comparison
Compare IPSC & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- MAIA
- Stock Information
- Founded
- IPSC 2019
- MAIA 2018
- Country
- IPSC United States
- MAIA United States
- Employees
- IPSC 165
- MAIA N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- MAIA Health Care
- Exchange
- IPSC Nasdaq
- MAIA Nasdaq
- Market Cap
- IPSC 49.6M
- MAIA 46.7M
- IPO Year
- IPSC 2021
- MAIA 2022
- Fundamental
- Price
- IPSC $0.58
- MAIA $1.79
- Analyst Decision
- IPSC Strong Buy
- MAIA
- Analyst Count
- IPSC 5
- MAIA 0
- Target Price
- IPSC $3.33
- MAIA N/A
- AVG Volume (30 Days)
- IPSC 868.9K
- MAIA 371.3K
- Earning Date
- IPSC 08-07-2025
- MAIA 08-08-2025
- Dividend Yield
- IPSC N/A
- MAIA N/A
- EPS Growth
- IPSC N/A
- MAIA N/A
- EPS
- IPSC N/A
- MAIA N/A
- Revenue
- IPSC $114,898,000.00
- MAIA N/A
- Revenue This Year
- IPSC $1,064.82
- MAIA N/A
- Revenue Next Year
- IPSC N/A
- MAIA N/A
- P/E Ratio
- IPSC N/A
- MAIA N/A
- Revenue Growth
- IPSC 8286.72
- MAIA N/A
- 52 Week Low
- IPSC $0.34
- MAIA $1.40
- 52 Week High
- IPSC $3.29
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- IPSC 52.16
- MAIA 47.69
- Support Level
- IPSC $0.58
- MAIA $1.66
- Resistance Level
- IPSC $0.66
- MAIA $1.95
- Average True Range (ATR)
- IPSC 0.04
- MAIA 0.10
- MACD
- IPSC -0.00
- MAIA -0.00
- Stochastic Oscillator
- IPSC 41.52
- MAIA 23.28
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.